Beam Therapeutics BEAM Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's stock issuance proceeds?
- Beam Therapeutics (BEAM) reported stock issuance proceeds of $2.03M in Q1 2026.
- How has Beam Therapeutics's stock issuance proceeds changed year-over-year?
- Beam Therapeutics's stock issuance proceeds increased by 181.6% year-over-year, from $719K to $2.03M.
- What is the long-term trend for Beam Therapeutics's stock issuance proceeds?
- Over 4 years (2021 to 2025), Beam Therapeutics's stock issuance proceeds has grown at a -71.8% compound annual growth rate (CAGR), from $757.45M to $4.77M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.